Nootropics

Adrafinil

Evidence: moderate_human

Mechanism of Action

Inactive prodrug that is hepatically metabolized to modafinil (via hepatic amidase enzymes) and its inactive acid metabolite modafinilic acid. The active metabolite modafinil then exerts its effects as a DAT inhibitor with downstream orexinergic, histaminergic, and noradrenergic activation. Conversion is incomplete — approximately 33-50% of adrafinil is converted to modafinil, with the remainder forming inactive metabolites. The hepatic first-pass metabolism means onset is delayed (60-90 minutes vs. 30-60 minutes for modafinil).

Dosing Protocol

Standard: 300-600 mg once daily (for educational context — unregulated prodrug of a prescription medication)

Maintenance: 300 mg/day; 600 mg is the commonly used dose to approximate 200 mg modafinil

Administration: oral

Timing: Early morning on an empty stomach for faster hepatic conversion. Onset delayed 60-90 minutes. Avoid afternoon/evening dosing due to long effective duration.

Duration: Short-term or intermittent use strongly preferred. Avoid continuous daily use exceeding 3 months without liver function monitoring.

Notes

FOR EDUCATIONAL PURPOSES ONLY. Adrafinil exists primarily as an unregulated alternative to prescription modafinil in jurisdictions where modafinil requires a prescription. The key disadvantage is the obligatory hepatic conversion step, which creates three problems: (1) delayed onset, (2) hepatic strain with chronic use, and (3) incomplete conversion meaning higher doses are needed. Liver function tests (ALT/AST) should be monitored if used for more than a few weeks. Olmifon was withdrawn from the French market in 2011 — some interpret this as a safety signal, though the withdrawal was also related to the availability of modafinil as a superior alternative. For most users, obtaining a prescription for modafinil is preferable to accepting adrafinil's hepatotoxicity risk.

Stacking

  • L-Theanine
  • Alpha-GPC
  • Milk Thistle (hepatoprotective adjunct)

Interactions

  • Hepatotoxic drugs (Acetaminophen, Statins, etc.) [HIGH] — Additive hepatic burden; adrafinil's hepatic metabolism may compound liver enzyme elevation
  • Hormonal contraceptives [HIGH] — Active metabolite modafinil induces CYP3A4, reducing contraceptive efficacy
  • CYP2C19 substrates [MEDIUM] — Modafinil metabolite inhibits CYP2C19
  • Warfarin [MEDIUM] — Active metabolite may alter warfarin metabolism
  • Alcohol [MEDIUM] — Combined hepatic burden; increased risk of liver enzyme elevation

Contraindications

  • Hepatic impairment of any severity
  • Concurrent hepatotoxic medication
  • All contraindications for modafinil apply (cardiac conditions, anxiety disorders, pregnancy)
  • History of liver disease or elevated liver enzymes

Side Effects

  • All modafinil side effects apply
  • Elevated liver enzymes (ALT/AST)
  • Potential hepatotoxicity with chronic use
  • Skin reactions
  • GI distress (more common than with modafinil due to hepatic metabolism)

Key Papers

  • 10.1111/j.1527-3458.1999.tb00100.x
  • 10.1080/08897077.2019.1700584

Source Quality

Unregulated in most countries (not scheduled, but sold as a research chemical or supplement). Was marketed as Olmifon in France but discontinued in 2011 due to safety concerns and availability of modafinil. Available from nootropic/research chemical vendors — quality is highly variable. Demand third-party CoA with HPLC purity >98%. No pharmaceutical-grade product currently exists.

Disclaimer: This information is for educational purposes only and is not medical advice. BioAccelera Labs does not diagnose, treat, or prescribe. Consult a licensed healthcare provider before using any compound.

Should Adrafinil Be in Your Stack?

Take the free assessment and get personalized recommendations based on your biology and goals.

Get Your Free Protocolor take the assessment →
← Browse All 231 Compounds